QIAGEN logo

Detect SARS-CoV-2 infection in just 2 minutes

The QIAreach™ SARS-CoV-2 Antigen Test is a scalable, digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen. The QIAreach SARS-CoV-2 Antigen Test lets you test up to 8 patients simultaneously for SARS-CoV-2 infection with first positive results in just 2 minutes.

Access to SARS-CoV-2 antigen testing made possible

Fast and flexible

  • Random access testing of 1–8 samples
  • More than 30 tests per hour on each eHub
  • Walk-away testing with results in 2–15 minutes

Accessible

  • Nasopharyngeal swab specimens
  • Minimal lab requirements
  • No maintenance or calibration required

Trustworthy

  • 90% test sensitivity, 100% test specificity
  • Objective, reproducible results
  • State-of-the-art nanoparticle fluorescence detection

Portable and Connected

  • Small, battery-operated eHub
  • Automated transfer of data to optional software
  • Connectible to LIMS

16x9imge

As part of the complete QIAreach solution for SARS-CoV-2 testing, the QIAreach SARS-CoV-2 Antigen Test will run simultaneously with the QIAreach Anti-SARS-CoV-2 Total Test on a single QIAreach eHub.

Thank you for your interest in QIAseq HRR panel.

Download brochure

Contact your QIAGEN sales representative to learn more.

hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
hiddenWithCSS
I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.

Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation All information you provide in this site will be governed by our Privacy Policy

QIAreach Anti-SARS-CoV-2 Total and QIAreach SARS-CoV-2 Antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform high complexity tests.

QIAreach Anti-SARS-CoV-2 Total Test:

  • This test has not been reviewed by the FDA. 
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

QIAreach SARS-CoV-2 Antigen Test:

  • The QIAreach SARS-CoV-2 Antigen Test has been validated but FDA’s independent review of this validation is pending. 

Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.